TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06627530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide Oral Tablet
Description: darolutamide 600 mg PO BID for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide Oral Tablet
Description: darolutamide 600 mg PO BID for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: leuprorelin depot 22.5 mg SC every 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin
Description: leuprorelin depot 22.5 mg SC every 12 weeks
Study: NCT05697432

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plaque index
Description: An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Streptococcus mutans screening
Description: A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
Study: NCT05445687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative language intervention program
Description: Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative language intervention program
Description: Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional language intervention
Description: Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
Study: NCT05812599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Module
Description: The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
Study: NCT05034887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan (T-DXd) monotherapy
Description: T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd, Durvalumab and Capecitabine Combination
Description: Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
Study: NCT05592730

Intervention type: GENETIC
Intervention: AMHR2 polymorphism in blood
Description: 1 tube of blood taken at the first application

Intervention type: GENETIC
Intervention: AMHR2 polymorphism in blood
Description: 1 tube of blood taken at the first application

Intervention type: GENETIC
Intervention: AMHR2 polymorphism in blood
Description: 1 tube of blood taken at the first application

Intervention type: GENETIC
Intervention: AMHR2 polymorphism in granulosa cell
Description: Extraction of granulosa cell from the follicle fluid obtained during OPU

Intervention type: GENETIC
Intervention: AMHR2 polymorphism in granulosa cell
Description: Extraction of granulosa cell from the follicle fluid obtained during OPU
Study: NCT05333081

Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of rice for evaluation of the glycemic index
Description: The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
Study: NCT05384002

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)
Study: NCT06173310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care Portable Perfusion Phantom (P4)
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Study: NCT05573906

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for anxiety plus benzodiazepine taper
Description: 11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Health education control plus benzodiazepine taper
Description: 11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
Study: NCT05064631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial Lysate
Description: Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacterial Lysate
Description: Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
Study: NCT05854784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide 16 MG
Description: Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
Study: NCT05760677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
Description: the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
Description: the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
Study: NCT04896580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature based exercise
Description: Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
Study: NCT06468839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital addiction management model
Description: The experimental group will implement a digital addiction model. No intervention will be made to the control group.
Study: NCT05760677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar
Description: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar
Description: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
Study: NCT05174702

Intervention type: RADIATION
Intervention: Irradiation collected at the end of the operation on the active dosimeter
Description: Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team

Intervention type: RADIATION
Intervention: Irradiation collected at the end of the operation on the active dosimeter
Description: Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
Study: NCT06293859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic oat flakes
Description: 2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
Study: NCT05453253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed second dose of oral cholera vaccine, Euvichol-Plus
Description: The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed second dose of oral cholera vaccine, Euvichol-Plus
Description: The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
Study: NCT06293859

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional oat flakes
Description: Commercial oat flakes
Study: NCT06702423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-based chatbot
Description: A tailored Japanese HPV vaccination chatbot.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: A publicly accessible HPV vaccination leaflet prepared by the Ministry of Health, Labour, and Welfare.
Study: NCT05718999

Intervention type: DIAGNOSTIC_TEST
Intervention: Not intervention
Description: Not having intervention is an observational study

Intervention type: DIAGNOSTIC_TEST
Intervention: Not intervention
Description: Not having intervention is an observational study
Study: NCT05453253

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
Description: Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year.
Study: NCT05084989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
Description: 2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part1: Placebo
Description: 2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
Study: NCT06191211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing, AIMS
Description: Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility engagement
Description: A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
Study: NCT05084989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part2: Recombinant two-component COVID-19 vaccine (CHO cell)
Description: 1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part2: COVID-19 Vaccine, mRNA
Description: 1 dose. Intramuscular injection, 30 μg/0.3 mL.
Study: NCT05906446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent (Exercise + Protein Supplementation)
Description: * Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised
Study: NCT06191211

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facility engagement
Description: A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
Study: NCT05857956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proper Wild energy shot
Description: 100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
Study: NCT06213701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: HMP is a 4-week mobile health (mHealth) meditation training program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation app
Description: Psychoeducation app
Study: NCT04760132

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COMIRNATY - BioNTech Manufacturing GmbH
Description: Vaccination as part of the the Danish national government programme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH
Description: Vaccination as part of the the Danish national government programme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine AstraZeneca suspension for injection
Description: Vaccination as part of the the Danish national government programme
Study: NCT05798962

Intervention type: PROCEDURE
Intervention: Biopsies
Description: Biopsies from the pathological muscle and healthy, unaffected muscle

Intervention type: PROCEDURE
Intervention: Biopsies
Description: Biopsies from the pathological muscle and healthy, unaffected muscle

Intervention type: PROCEDURE
Intervention: Biopsies
Description: Biopsies from the pathological muscle and healthy, unaffected muscle
Study: NCT05574972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timing Carotid Stent
Description: all the participants in this group will be performed with Timing Carotid Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Wallstent
Description: all the participants in this group will be performed with Carotid Wallstent
Study: NCT05976737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Study: NCT06223425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality Situation-Based Flipped Learning
Description: Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
Study: NCT05278793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: Ferrous fumarate 200mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: Ferrous fumarate 200mg oral
Study: NCT04567732

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: injection of Filtered Autologous Adipose Tissue
Description: Single injection of Filtered Autologous Adipose Tissue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of Placebo
Study: NCT05449483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab+ Paclitaxel + Cisplatin
Description: tislelizumab combined with chemotherapy
Study: NCT05445687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional language intervention
Description: Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
Study: NCT05603819

Intervention type: DEVICE
Intervention: EDIT-B
Description: To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.

Intervention type: DEVICE
Intervention: EDIT-B
Description: To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
Study: NCT05475171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Given by vein (IV)
Study: NCT06103669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative local therapy
Description: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Study: NCT04999293

Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.